BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is headquartered in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BTAI
CUSIPN/A
Phone203-643-8060
Debt
Debt-to-Equity RatioN/A
Current Ratio37.01
Quick Ratio37.01
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees6
Outstanding Shares15,650,000
Market Cap$144.72 million
BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions
What is BioXcel Therapeutics' stock symbol?
BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."
How were BioXcel Therapeutics' earnings last quarter?
BioXcel Therapeutics Inc (NASDAQ:BTAI) announced its quarterly earnings data on Wednesday, August, 8th. The company reported ($0.19) EPS for the quarter, topping the Zacks' consensus estimate of ($0.32) by $0.13. View BioXcel Therapeutics' Earnings History.
When is BioXcel Therapeutics' next earnings date?
What price target have analysts set for BTAI?
5 Wall Street analysts have issued 12-month price objectives for BioXcel Therapeutics' stock. Their predictions range from $15.00 to $25.00. On average, they expect BioXcel Therapeutics' share price to reach $20.40 in the next year. This suggests a possible upside of 150.6% from the stock's current price. View Analyst Price Targets for BioXcel Therapeutics.
What is the consensus analysts' recommendation for BioXcel Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioXcel Therapeutics.
What are Wall Street analysts saying about BioXcel Therapeutics stock?
Here are some recent quotes from research analysts about BioXcel Therapeutics stock:
- 1. According to Zacks Investment Research, "BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States. " (8/14/2018)
- 2. Canaccord Genuity analysts commented, "We hosted BTAI’s CEO Vimal Mehta at our 2018 Boston, MA. CSO Frank Yocca, CMO Vincent O’Neill, and CFO Richard Steinhart were also in the audience. While we did not learn anything significantly new, we note the company appears very confident in its ability to hit its stated development timelines on its two product candidates: BXCL501 (sublingual dexmedetomidine), which is a neurology product for agitation that is in BXCL701, which is an oncology product for treatment-emergent neuroendocrine prostate cancer and pancreatic cancer. We continue to view the stock as an interesting oncology and neurology play, and are reiterating our BUY; see our recent initiation here for more details." (8/10/2018)
- 3. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a discounted cash flow (DCF)-based assessment, which yields a total rNPV of $335M for for BXCL701. We thus derive a total enterprise value of $455M, which translates into a price objective of $25.00 based on 18M fully-diluted shares outstanding as of mid-2019." (8/1/2018)
Who are some of BioXcel Therapeutics' key competitors?
Some companies that are related to BioXcel Therapeutics include Insys Therapeutics (INSY), Evolus (EOLS), Obseva (OBSV), TIGENIX/S (TIG), CannTrust (CNTTF), Aclaris Therapeutics (ACRS), Beyondspring (BYSI), Arcus Biosciences (RCUS), Arbutus Biopharma (ABUS), Lannett (LCI), Theratechnologies (THERF), Odonate Therapeutics (ODT), Kindred Biosciences (KIN), Five Prime Therapeutics (FPRX) and Unum Therapeutics (UMRX).
Who are BioXcel Therapeutics' key executives?
BioXcel Therapeutics' management team includes the folowing people:
- Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, Sec. & Director (Age 57)
- Mr. Richard I. Steinhart MBA, Chief Financial Officer (Age 61)
- Dr. Frank D. Yocca Ph.D., Chief Scientific Officer (Age 62)
- Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 49)
- Dr. Luca Rastelli, VP of Oncology R&D (Age 50)
When did BioXcel Therapeutics IPO?
(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
When does the company's lock-up period expire?
BioXcel Therapeutics' lock-up period expires on Tuesday, September 4th. BioXcel Therapeutics had issued 5,454,545 shares in its public offering on March 8th. The total size of the offering was $59,999,995 based on an initial share price of $11.00. After the end of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Has BioXcel Therapeutics been receiving favorable news coverage?
News stories about BTAI stock have been trending somewhat positive recently, Accern reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioXcel Therapeutics earned a media and rumor sentiment score of 0.17 on Accern's scale. They also gave media stories about the company an impact score of 44.63 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for BioXcel Therapeutics.
Who are BioXcel Therapeutics' major shareholders?
BioXcel Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (1.91%), Point72 Asset Management L.P. (0.42%), BlackRock Inc. (0.10%) and Dean Capital Investments Management LLC (0.08%).
Which major investors are selling BioXcel Therapeutics stock?
BTAI stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Dean Capital Investments Management LLC.
Which major investors are buying BioXcel Therapeutics stock?
BTAI stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc. and Point72 Asset Management L.P..
How do I buy shares of BioXcel Therapeutics?
Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioXcel Therapeutics' stock price today?
One share of BTAI stock can currently be purchased for approximately $8.14.
How big of a company is BioXcel Therapeutics?
BioXcel Therapeutics has a market capitalization of $144.72 million. BioXcel Therapeutics employs 6 workers across the globe.
How can I contact BioXcel Therapeutics?
BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-643-8060 or via email at [email protected]
MarketBeat Community Rating for BioXcel Therapeutics (NASDAQ BTAI)
MarketBeat's community ratings are surveys of what our community members think about BioXcel Therapeutics and other stocks. Vote "Outperform" if you believe BTAI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTAI will underperform the S&P 500 over the long term. You may vote once every thirty days.
